{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T03:42:01Z","timestamp":1768448521718,"version":"3.49.0"},"reference-count":22,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,12,28]],"date-time":"2017-12-28T00:00:00Z","timestamp":1514419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2018,2]]},"abstract":"Abstract<\/jats:title>We conducted a surveillance epidemiology and end results (SEER<\/jats:styled-content>)\u2010based analysis to describe the incidence and characteristics of second primary acute lymphoblastic leukemia (sALL<\/jats:styled-content>) among adults (\u226518\u00a0years) with a history of primary malignancies (1M). Standardized incidence ratios (SIR<\/jats:styled-content>s) of sALL<\/jats:styled-content> cases were calculated by site and 1M stage. We also evaluated the differences in 5\u2010year sALL<\/jats:styled-content> survival by age, site, and extent of 1M, latency of sALL<\/jats:styled-content> after 1M, and evidence of underlying racial\/ethnic disparity. We identified 10,956 patients with de\u2010novo\/primary acute lymphoblastic leukemia (1ALL<\/jats:styled-content>) and 772 with sALL<\/jats:styled-content>. Women (49.1% vs. 42.9%), white patients (72.0% vs. 59.5%), older patients (58.8% vs. 25.2%; age \u226565\u00a0years), and patients diagnosed between 2003 and 2012 (66.8% vs. 53.9%) had a higher proportion of sALL<\/jats:styled-content> compared with 1ALL<\/jats:styled-content>. There was a significantly inferior median 5\u2010year survival for sALL<\/jats:styled-content> patients compared to 1ALL<\/jats:styled-content> (6 vs. 15\u00a0months; HR<\/jats:styled-content> 1.20, 95% CI<\/jats:styled-content> 1.10\u20131.31, P<\/jats:italic>\u00a0<\u00a00.001). The median latency period was 60.0\u00a0months; the most common 1M among sALL<\/jats:styled-content> patients were breast (17.9%) and prostate (17.4%). Patients with any 1M were at increased risk of developing sALL<\/jats:styled-content> (SIR<\/jats:styled-content> 1.76, 95% CI<\/jats:styled-content> 1.58\u20131.95, P<\/jats:italic>\u00a0<\u00a00.001). Hematological\u20101M sites had significantly higher SIR<\/jats:styled-content>s (hematological\u2010SIR<\/jats:styled-content> 7.35; solid\u2010SIR<\/jats:styled-content> 1.33; P<\/jats:italic>\u00a0<\u00a00.001). We observed a significant increase in sALL<\/jats:styled-content> incidence after a 1M and a significantly worse 5\u2010year survival with different demographic characteristics from 1ALL<\/jats:styled-content>. There is a need to define appropriate screening methods for patients surviving their primary cancer.<\/jats:p>","DOI":"10.1002\/cam4.1266","type":"journal-article","created":{"date-parts":[[2017,12,28]],"date-time":"2017-12-28T06:08:39Z","timestamp":1514441319000},"page":"499-507","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Second primary acute lymphoblastic leukemia in adults: a SEER<\/scp> analysis of incidence and outcomes"],"prefix":"10.1002","volume":"7","author":[{"given":"Abhisek","family":"Swaika","sequence":"first","affiliation":[{"name":"Division of Hematology & Medical Oncology Mayo Clinic Jacksonville Florida"},{"name":"Mayo Clinic Cancer Center Jacksonville Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan D.","family":"Frank","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics Mayo Clinic Rochester Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongyun","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine Norris Comprehensive Cancer Center University of Southern California Los Angeles California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura E.","family":"Finn","sequence":"additional","affiliation":[{"name":"Division of Hematology & Medical Oncology Mayo Clinic Jacksonville Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liuyan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Division of Hematopathology Department of Pathology and Laboratory Medicine Mayo Clinic Jacksonville Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Advani","sequence":"additional","affiliation":[{"name":"Division of Hematology & Medical Oncology Mayo Clinic Jacksonville Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asher A.","family":"Chanan\u2010Khan","sequence":"additional","affiliation":[{"name":"Division of Hematology & Medical Oncology Mayo Clinic Jacksonville Florida"},{"name":"Mayo Clinic Cancer Center Jacksonville Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-8111","authenticated-orcid":false,"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[{"name":"Division of Hematology & Medical Oncology Mayo Clinic Jacksonville Florida"},{"name":"Mayo Clinic Cancer Center Jacksonville Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1673-1708","authenticated-orcid":false,"given":"James M.","family":"Foran","sequence":"additional","affiliation":[{"name":"Division of Hematology & Medical Oncology Mayo Clinic Jacksonville Florida"},{"name":"Mayo Clinic Cancer Center Jacksonville Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,12,28]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"http:\/\/seer.cancer.gov\/statfacts\/html\/alyl.html 2016"},{"key":"e_1_2_7_3_1","volume-title":"New malignancies among cancer survivors: SEER cancer registries, 1973\u20132000","author":"Curtis R. E.","year":"2006"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.6585"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01636.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26735"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402918"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009113377"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn182"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2015.09.011"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(98)00193-3"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13386"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.057752"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-006-9460-0"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70609-0"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262"},{"key":"e_1_2_7_17_1","unstructured":"https:\/\/seer.cancer.gov\/tools\/mphrules\/ 2016"},{"key":"e_1_2_7_18_1","unstructured":"https:\/\/seer.cancer.gov\/seerstat\/tutorials\/mpsir1a\/webprint\/ 2017"},{"key":"e_1_2_7_19_1","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1182\/blood.V124.21.935.935","article-title":"Secondary acute lymphoblastic leukemia after primary solid organ malignancy: a SEER analysis of incidence and outcomes","volume":"124","author":"Swaika A.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-008-9256-0"},{"key":"e_1_2_7_21_1","unstructured":"http:\/\/seer.cancer.gov\/statfacts\/html\/breast.html 2016"},{"key":"e_1_2_7_22_1","unstructured":"http:\/\/seer.cancer.gov\/statfacts\/html\/prost.html 2016"},{"key":"e_1_2_7_23_1","unstructured":"http:\/\/seer.cancer.gov\/statfacts\/html\/lungb.html 2016"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.1266","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.1266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T03:55:19Z","timestamp":1695786919000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.1266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,28]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1002\/cam4.1266"],"URL":"https:\/\/doi.org\/10.1002\/cam4.1266","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,28]]},"assertion":[{"value":"2017-06-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}